Sarkawt Hamad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sarkawt Hamad has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Kurt Pfannkuche
Center for Physiology and Pathophysiology, Institute for Physiology I University and University Hospital of Cologne Cologne Germany
2 shared publications Agapios Sachinidis
Center for Physiology and Pathophysiology, Physiology I, University and University Hospital of Cologne, Cologne, Germany
1 shared publicationAlbert Teis
Center for Physiology and Pathophysiology, Physiology I, University and University Hospital of Cologne, Cologne, Germany
1 shared publicationAntoni Bayes-Genis
ICREC Research Program, Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain
1 shared publicationAstrid Schauss
Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Imaging Facility, Cologne, Germany
1 shared publication- Astrid Schauss
Cologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany
1 shared publication
Latest Publications
- Open Access
- 23 April 2026
- Published by Ivyspring International Publisher in Theranostics
- Vol. 16 (12) , 6437-6462
Scalable differentiation of human cardiac organoids from iPSCs generates cardiac tissues for cardiac cell therapy
Rationale: Cardiac organoids have the potential to overcome the limitations of cell-based therapies for myocardial infarction, particularly by improving cell engraftment.
- 23 April 2026
- Published by Ivyspring International Publisher in Theranostics
- Vol. 16 (12) , 6437-6462
Open AccessScalable differentiation of human cardiac organoids from iPSCs generates cardiac tissues for cardiac cell therapy
Rationale: Cardiac organoids have the potential to overcome the limitations of cell-based therapies for myocardial infarction, particularly by improving cell engraftment.
- Open Access
- 16 June 2025
- Published by MDPI AG in Bioengineering
- Vol. 12 (6) , 657
Cell-Based Therapies: Ferromagnetic Versus Superparamagnetic Cell Targeting
Stem-cell-based therapies rely on the transplantation of stem cells or stem-cell-derived organotypic cells into injured tissues in order to improve or restore tissue function that has been impaired by various diseases. The potential of induced pluripotent stem cells has created many applications in the field of cell therapy, for example. Some applications, for example, those in cardiac cell therapy, suffer from low or very low efficiencies of cell engraftment. Therefore, magnetic cell targeting can be discussed as a method for capturing superparamagnetic nanoparticle-labelled cells in the tissue. Here, we employ superparamagnetic iron oxide nanoparticles (SPIONs) for the intracellular magnetic loading of mesenchymal stem cells (MSCs). In addition, we test a novel strategy of labelling MSCs with ferromagnetic particles. The adhesion assays demonstrate a faster adhesion kinetic of SPIONs-loaded MSC spheroids when a magnetic field was applied, resulting in >50% spheroid adhesion after 30 min. Clustering of cells inside the magnetic field is a second potential mechanism of magnetic cell retention and >80% of cells were found to be aggregated in clusters when placed in a magnetic field for 10 min. SPIONs-loaded and ferromagnetic-particle-loaded cells performed equally in the cell clustering assay. In conclusion, the clustering of SPION-labelled cells explains the observation that magnetic targeting reaches maximal efficiency in vivo after only 10 min of magnetic field application. This has significant implications for magnetic-targeting-assisted stem cell and cell replacement therapies.
- 16 June 2025
- Published by MDPI AG in Bioengineering
- Vol. 12 (6) , 657
Open AccessCell-Based Therapies: Ferromagnetic Versus Superparamagnetic Cell Targeting
Stem-cell-based therapies rely on the transplantation of stem cells or stem-cell-derived organotypic cells into injured tissues in order to improve or restore tissue function that has been impaired by various diseases. The potential of induced pluripotent stem cells has created many applications in the field of cell therapy, for example. Some applications, for example, those in cardiac cell therapy, suffer from low or very low efficiencies of cell engraftment. Therefore, magnetic cell targeting can be discussed as a method for capturing superparamagnetic nanoparticle-labelled cells in the tissue. Here, we employ superparamagnetic iron oxide nanoparticles (SPIONs) for the intracellular magnetic loading of mesenchymal stem cells (MSCs). In addition, we test a novel strategy of labelling MSCs with ferromagnetic particles. The adhesion assays demonstrate a faster adhesion kinetic of SPIONs-loaded MSC spheroids when a magnetic field was applied, resulting in >50% spheroid adhesion after 30 min. Clustering of cells inside the magnetic field is a second potential mechanism of magnetic cell retention and >80% of cells were found to be aggregated in clusters when placed in a magnetic field for 10 min. SPIONs-loaded and ferromagnetic-particle-loaded cells performed equally in the cell clustering assay. In conclusion, the clustering of SPION-labelled cells explains the observation that magnetic targeting reaches maximal efficiency in vivo after only 10 min of magnetic field application. This has significant implications for magnetic-targeting-assisted stem cell and cell replacement therapies.